41,035 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Acquired by Bryce Point Capital LLC

Bryce Point Capital LLC bought a new stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 41,035 shares of the company's stock, valued at approximately $497,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Hillsdale Investment Management Inc. boosted its holdings in Elanco Animal Health by 2.1% in the 4th quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company's stock valued at $524,000 after purchasing an additional 900 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Elanco Animal Health by 0.8% in the fourth quarter. Arizona State Retirement System now owns 143,462 shares of the company's stock valued at $1,737,000 after buying an additional 1,166 shares in the last quarter. MTM Investment Management LLC grew its holdings in Elanco Animal Health by 9.3% during the fourth quarter. MTM Investment Management LLC now owns 14,168 shares of the company's stock worth $172,000 after acquiring an additional 1,200 shares during the period. M&T Bank Corp raised its position in Elanco Animal Health by 5.9% in the third quarter. M&T Bank Corp now owns 26,407 shares of the company's stock worth $388,000 after acquiring an additional 1,464 shares in the last quarter. Finally, Blue Trust Inc. raised its position in Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after acquiring an additional 1,894 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN traded up $1.09 on Wednesday, hitting $9.42. The company had a trading volume of 12,593,899 shares, compared to its average volume of 4,878,409. The business has a 50 day moving average of $10.71 and a 200 day moving average of $12.10. Elanco Animal Health Incorporated has a 52-week low of $8.03 and a 52-week high of $18.80. The company has a market cap of $4.68 billion, a PE ratio of 23.55, a PEG ratio of 2.50 and a beta of 1.44. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter last year, the firm earned $0.08 earnings per share. The business's quarterly revenue was down 1.4% compared to the same quarter last year. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Transactions at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, March 11th. The shares were purchased at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the acquisition, the director now owns 111,459 shares of the company's stock, valued at $1,136,881.80. The trade was a 9.86 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.57% of the company's stock.

Analysts Set New Price Targets

ELAN has been the topic of a number of recent analyst reports. Stifel Nicolaus lowered their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. UBS Group dropped their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Morgan Stanley decreased their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 26th. Barclays dropped their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Finally, Piper Sandler decreased their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $15.17.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.